文献速递艾滋病与性传播感染

多替拉韦/拉米夫定双药方案治疗CD4<200/mm³初治HIV感染者的48周疗效与安全性:DOLCE研究

Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.
PubMed 文献 · Clin Infect Dis · 2026-01-01

DOLCE研究是一项随机、开放标签、多中心试验,评估多替拉韦/拉米夫定双药方案在CD4计数≤200 cells/mm³的初治HIV感染者中的抗病毒疗效。48周时,双药组病毒学抑制率(pVL<50 copies/mL)为82.2%,CD4计数增加+200 cells/mm³,严重不良事件发生率为11.1%。结果表明该双药方案在低CD4和高病毒载量人群中具有高疗效。

要点

  • 多替拉韦/拉米夫定双药方案在CD4≤200 cells/mm³初治HIV感染者中48周病毒学抑制率达82.2%。
  • 双药组CD4计数平均增加+200 cells/mm³,严重不良事件发生率11.1%。
  • 该方案疗效不受基线CD4计数和病毒载量影响。

核心结论

  • 多替拉韦/拉米夫定双药方案在低CD4计数和高病毒载量的初治HIV感染者中显示出高疗效和良好安全性。

研究设计与样本

  • DOLCE研究为随机、假设检验、开放标签、多中心试验,将初治HIV感染者按2:1随机分配至多替拉韦/拉米夫定双药组或多替拉韦+替诺福韦/恩曲他滨(或拉米夫定)三药组。

主要发现

  • 48周时,双药组病毒学抑制(pVL<50 copies/mL)比例为82.2%(125/152),符合方案分析应答率为91.9%。
  • 双药组CD4计数增加+200 cells/mm³。
  • 152例参与者中15例(11.1%)报告严重不良事件(n=17)。

关键数值与推荐

  • 主要终点为48周时pVL<50 copies/mL的参与者比例(FDA快照分析意向治疗暴露人群)。

临床怎么用

  • 对于CD4计数≤200 cells/mm³的初治HIV感染者,多替拉韦/拉米夫定双药方案可作为考虑选项,但需结合患者具体情况评估。

局限性

  • 原文未报告三药对照组48周病毒学抑制率的具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dolutegravir (DTG)/lamivudine dual therapy (DT) has demonstrated noninferiority to triple therapy (TT) in the GEMINI trials. Although the population with ≤200 CD4 cells/mm3 had a lower response rate, this was unrelated to virological failure. This trial evaluated the antiviral activity of dolutegravir/lamivudine among antiretroviral therapy (ART)-naive patients with human immunodeficiency virus (HIV) with a CD4 count ≤200 cells/mm3. METHODS: DOLCE is a randomized, hypothesis-based, open-label, multicenter study l, assessing the antiviral efficacy of DTG/3TC at week 48 in treatment-naive people with HIV (PWH) with CD4 counts ≤200 cells/mm3. Participants were randomly assigned in a 2:1 ratio to receive DTG/3TC as a single tablet regimen or DTG plus Tenofovir disoproxil fumarate (TDF)/XTC: Emtricitabine or lamivudine (FTC or 3TC). The primary endpoint was the proportion of participants with pVL <50 copies/mL at week 48 (Food and Drug Administration snapshot analysis intent-to-treat exposed population). This report presents results at week 48. RESULTS: Baseline characteristics were similar in both arms. In the DT arm, median CD4 cell count was 109 cells/mm (interquartile range [IQR]: 49-177) and median pVL was 180,000 copies/mL (IQR: 53 309-468 691); 45.4% had CD4 <100 cells/mm3, and 61.4% had pVL >100 000 copies/mL. CDC (Centers for Disease Control and Prevention) stage C: 31.4%. At week 48, virological suppression (pVL <50 copies/mL) was achieved 82.2% in the DT (125/152), and the CD4 count increased by +200 cells/mm3. Per-protocol analysis showed a response rate of 91.9%. Severe adverse events (n = 17) were reported in 15 of 152 participants (11.1%). CONCLUSIONS: Dolutegravir/3TC demonstrated high efficacy in a population with low CD4 counts and high viral load. This study adds information regarding the efficacy and safety of DTG/3TC, regardless of baseline CD4 counts and viral load. CLINICAL TRIALS REGISTRATION: NCT04880395.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Figueroa MI, Brites C, Cecchini D, et al. Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study. Clin Infect Dis. 2026. PMID: 40874763. doi:10.1093/cid/ciaf415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。